Updates are available Correction dated 2023-04-24
Click to view Correction: https://doi.org/10.1007/s00415-023-11721-2
-
Authors
Scutelnic, Adrian https://orcid.org/0000-0001-9053-584X
Justus, Lucie
Branca, Mattia
Meinel, Thomas R.
Beyeler, Morin
Silimon, Norbert
Drop, Boudewijn R.H.
Seiffge, David J.
Fischer, Urs
Arnold, Marcel
Mattle, Heinrich P.
Schankin, Christoph J.
Jung, Simon
-
Funding
Funding for this research was provided by:
Schweizerische Herzstiftung (FF21070)
- License Information
-
More Information
Article History
Received: 9 February 2023
Revised: 27 March 2023
Accepted: 29 March 2023
First Online: 4 April 2023
Change Date: 24 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-023-11721-2
Declarations
:
: LJ, MB, MBr, MBe, TRM, SN, DB: none. AS and SJ report research support from the Swiss Heart Foundation. DS reports grants from Bangerter Rhyner Foundation during the conduct of the study; personal fees from Bayer, Alexion, and VarmX outside the submitted work. UF: consulting for Medtronic, Stryker, CSL Behring. Advisory boards for Portola/Alexion (money paid to institution). MA reports personal fees from AstraZeneca, Bayer, Bristol Myers Squibb, Covidien, Daiichy Sankyo, Medtronic, Novartis, Pfizer, and Amgen. HPM: Grants from Abbott for the PC and PRIMA trials and from Cerenovus for the ARISE studies. Personal and speaker fees from Cerenovus, Bayer, Servier, Medtronic and Stryker. CJS: consulting, advisory boards, speaker, travel support for/from Novartis, Eli Lilly, TEVA Pharmaceuticals, Allergan, Almirall, Amgen, Lundbeck, MindMed, Grünenthal. Part-time-employee at Zynnon.
